{"database": "lobbying", "table": "lobbying_activities", "rows": [[2021164, "7b10e64d-c25d-4541-b54c-d45115628e3e", "Q3", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2017, "third_quarter", "PHA", "S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \n\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. \n\nEducation activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. \n\nEducation activities related to the cross referencing of certain data related to Medicare Parts A, B and D. \n\nS. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. \n\nH.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. \n\nIssues related to the price of prescription medications in the United States.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2017-10-10T11:26:11.380000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2021164"], "units": {}, "query_ms": 0.3721109824255109, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}